News & Updates

Mortality is heightened among type 2 diabetes (T2D) patients with substantial weight loss, but such risk can be attenuated by improving lifestyle quality, suggests a recent study.

Telehealth strategies do not seem to ease the mental health burden in type 1 diabetes (T1D) patients during the coronavirus disease 2019 (COVID-19) pandemic, reports a recent Brazil study.

Development of type 2 diabetes (T2D) is more likely to occur among patients with thyroid cancer who underwent thyroidectomy than matched controls, a Korea study has shown. In addition, a U-shaped dose-dependent relationship exists between the levothyroxine dosage and T2D risk.

A real-world propensity score-matched study in Hong Kong finds that, compared with use of dipeptidyl peptidase-4 (DPP-4) inhibitors, use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes (T2D) patients is associated with lower risk of incident atrial fibrillation (AF), stroke/transient ischaemic attack (TIA), and cardiovascular (CV) and all-cause mortality.

Patients with type 1 diabetes mellitus (T1DM) may experience a temporary change in their blood glucose levels in the first week following COVID-19 vaccination, according to a small English study.

A mobile health intervention combining a smartphone app, a smart band, and counseling offers benefits in terms of weight loss, body composition variables, and time spent in light physical activity compared to counseling alone at 3 months among sedentary adults with overweight or obesity, results of the Evident 3 Study have shown.

Treatment with nonvitamin K antagonist oral anticoagulants (NOACs) results in lower risks of diabetes complications and mortality compared with warfarin in patients with atrial fibrillation (AF) and diabetes mellitus (DM), suggest a study.